HC Wainwright Forecasts Alumis’ Q1 Earnings (NASDAQ:ALMS)

Alumis Inc. (NASDAQ:ALMS) – Research analysts at HC Wainwright increased their Q1 2025 earnings per share (EPS) estimates for shares of Alumis in a research note issued to investors on Tuesday, April 22nd. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($1.03) for the quarter, up from their prior forecast of ($1.07). HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis’ Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.74) EPS and FY2025 earnings at ($3.22) EPS.

ALMS has been the topic of several other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a report on Thursday, March 20th. Oppenheimer started coverage on shares of Alumis in a research note on Thursday, January 30th. They issued an “outperform” rating and a $32.00 target price for the company. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $25.86.

Alumis Trading Down 8.5 %

Shares of Alumis stock opened at $4.31 on Thursday. Alumis has a 52 week low of $3.18 and a 52 week high of $13.53. The firm has a fifty day moving average of $5.52 and a two-hundred day moving average of $7.72.

Institutional Investors Weigh In On Alumis

Hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers grew its holdings in Alumis by 21.7% in the first quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock worth $102,000 after purchasing an additional 2,949 shares during the period. Tang Capital Management LLC grew its holdings in shares of Alumis by 40.6% during the fourth quarter. Tang Capital Management LLC now owns 600,000 shares of the company’s stock valued at $4,716,000 after buying an additional 173,406 shares during the last quarter. Foresite Capital Management V LLC grew its holdings in shares of Alumis by 3.5% during the fourth quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock valued at $45,426,000 after buying an additional 194,459 shares during the last quarter. BNP Paribas Financial Markets lifted its position in Alumis by 1,257.0% in the 4th quarter. BNP Paribas Financial Markets now owns 34,835 shares of the company’s stock valued at $274,000 after acquiring an additional 32,268 shares in the last quarter. Finally, Ally Bridge Group NY LLC boosted its stake in Alumis by 6.4% during the 4th quarter. Ally Bridge Group NY LLC now owns 445,259 shares of the company’s stock valued at $3,500,000 after purchasing an additional 26,843 shares during the last quarter.

Insiders Place Their Bets

In related news, CEO Martin Babler acquired 15,650 shares of the firm’s stock in a transaction that occurred on Tuesday, April 1st. The stock was acquired at an average cost of $6.44 per share, for a total transaction of $100,786.00. Following the completion of the acquisition, the chief executive officer now directly owns 106,454 shares of the company’s stock, valued at approximately $685,563.76. This trade represents a 17.23 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Alan Colowick bought 16,104 shares of the business’s stock in a transaction on Tuesday, April 1st. The shares were bought at an average cost of $6.97 per share, for a total transaction of $112,244.88. Following the completion of the acquisition, the director now directly owns 16,104 shares in the company, valued at approximately $112,244.88. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.